Interferon (IFN) therapy is nowadays widely used in clinical practice. In the literature, there are very few reports of the association between IFN therapy and pulmonary arterial hypertension (PAH), and current guidelines do not mention IFNs as a risk factor for PAH. We describe a patient with multiple sclerosis who developed severe PAH after treatment with IFN-beta-1a and the clinical response to sildenafil. Furthermore, we stress the need to further investigate the link between IFNs and PAH. Copyright (C) 2012 S. Karger AG, Basel
(2012). Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: A case report [journal article - articolo]. In CARDIOLOGY. Retrieved from https://hdl.handle.net/10446/235630
Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: A case report
Caravita, Sergio;
2012-01-01
Abstract
Interferon (IFN) therapy is nowadays widely used in clinical practice. In the literature, there are very few reports of the association between IFN therapy and pulmonary arterial hypertension (PAH), and current guidelines do not mention IFNs as a risk factor for PAH. We describe a patient with multiple sclerosis who developed severe PAH after treatment with IFN-beta-1a and the clinical response to sildenafil. Furthermore, we stress the need to further investigate the link between IFNs and PAH. Copyright (C) 2012 S. Karger AG, Basel| File | Dimensione del file | Formato | |
|---|---|---|---|
|
335064 (1).pdf
Solo gestori di archivio
Versione:
publisher's version - versione editoriale
Licenza:
Licenza default Aisberg
Dimensione del file
63.31 kB
Formato
Adobe PDF
|
63.31 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
Aisberg ©2008 Servizi bibliotecari, Università degli studi di Bergamo | Terms of use/Condizioni di utilizzo
